zoledronate

Mechanism: Zoledronate is a nitrogen-containing bisphosphonate that binds hydroxyapatite in bone and is internalized by osteoclasts during resorption. It inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, preventing prenylation of small GTPases (Ras, Rho, Rac) required for osteoclast cytoskeletal function, leading to osteoclast apoptosis and reduced bone resorption.

Clinical uses: (1) Osteoporosis (postmenopausal and glucocorticoid-induced) - annual IV infusion; (2) Hypercalcemia of malignancy - rapid onset, highly effective; (3) Paget's disease of bone; (4) Skeletal-related events from bone metastases (breast, prostate cancer, multiple myeloma) - reduces pathologic fractures, spinal cord compression, need for radiation/surgery.

Pharmacokinetics: Administered IV (unlike oral bisphosphonates like alendronate), avoiding GI absorption issues and esophagitis risk. Renally cleared - contraindicated/dose-adjusted in renal impairment (CrCl <35 mL/min).

Adverse effects: Acute phase reaction (flu-like symptoms, fever, myalgia) especially after first infusion; hypocalcemia (ensure adequate calcium/vitamin D before treatment); nephrotoxicity (monitor renal function); osteonecrosis of the jaw (especially with cancer-dose therapy, dental procedures); atypical femoral fractures with long-term use; ocular inflammation (rare).

Key distinction from denosumab: Zoledronate acts on existing osteoclasts via mevalonate pathway inhibition, has prolonged skeletal retention (effects persist after discontinuation), while denosumab is a RANKL inhibitor (monoclonal antibody) with rebound bone loss upon discontinuation.

Board relevance: Classic hypercalcemia of malignancy treatment; compare with other bisphosphonates (alendronate, risedronate - oral, for osteoporosis); understand osteoclast biology and mevalonate pathway; recognize ONJ and atypical fracture risk with prolonged use.